Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) by De Ruysscher, Dirk et al.
 
 
 
Progression-Free Survival and Overall Survival
Beyond 5 Years of NSCLC Patients With Synchronous
Oligometastases Treated in a Prospective Phase II
Trial (NCT 01282450)
Citation for published version (APA):
De Ruysscher, D., Wanders, R., Hendriks, L. E., van Baardwijk, A., Reymen, B., Houben, R., Bootsma,
G., Pitz, C., van Eijsden, L., & Dingemans, A-M. C. (2018). Progression-Free Survival and Overall Survival
Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II
Trial (NCT 01282450). Journal of Thoracic Oncology, 13(12), 1958-1961.
https://doi.org/10.1016/j.jtho.2018.07.098
Document status and date:
Published: 01/12/2018
DOI:
10.1016/j.jtho.2018.07.098
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 05 Jan. 2021
BRIEF REPORTProgression-Free Survival and Overall Survival
Beyond 5 Years of NSCLC Patients With
Synchronous Oligometastases Treated in a
Prospective Phase II Trial (NCT 01282450)Dirk De Ruysscher, MD, PhD,a,* Rinus Wanders, MD,b Lizza E. Hendriks, MD, PhD,c
Angela van Baardwijk, MD, PhD,b Bart Reymen, MD,b Ruud Houben, MSc,b
Gerben Bootsma, MD, PhD,d Cordula Pitz,e Linda van Eijsden, MD,f
Anne-Marie C. Dingemans, MD, PhDcaDepartment of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht
University Medical Center, Maastricht, The Netherlands
bMaastro Clinic, Maastricht, The Netherlands
cDepartment of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center,
Maastricht, The Netherlands
dDepartment of Pulmonology, Zuyderland Hospital, Geleen, The Netherlands
eDepartment of Pulmonology, Laurentius Hospital, Roermond, The Netherlands
fDepartment of Pulmonology, Sint Jans Gasthuis, Weert, The Netherlands
Received 22 May 2018; revised 20 July 2018; accepted 24 July 2018
Available online - 22 September 2018*Corresponding author.
Disclosure: Dr. De Ruysscher has been on the advisory boards of Astra
Zeneca, Bristol-Myers Squibb, Roche/Genentech, Merck/Pfizer, Cel-
gene, Noxxon, Mologen and has received investigator-initiated grants
from Bristol-Myers-Squibb and Boehringer Ingelheim outside of this
work. Dr. Hendriks has received research funding from Roche, has
been on the advisory board for Boehringer, Bristol-Myers Squibb and
has received travel reimbursement from Roche and Bristol-Myers
Squibb outside of this work. Dr. Dingemans has been on the advisory
boards for Boehringer, BMS, Roche, MSD, Lilly, Takeda, Pfizer outside
of this work. The remaining authors declare no conflict of interest.
Address for correspondence: Dirk De Ruysscher, MD, PhD, Maastro
Clinic, Dr. Tanslaan 12, 6229ET Maastricht, The Netherlands. E-mail:
dirk.deruysscher@maastro.nl
ª 2018 International Association for the Study of Lung Cancer.
Published by Elsevier Inc. All rights reserved.
ISSN: 1556-0864
https://doi.org/10.1016/j.jtho.2018.07.098ABSTRACT
Introduction: Two randomized studies have shown an
increased progression-free survival (PFS) by adding a
radical local treatment to systemic therapy in responding
patients with oligometastatic NSCLC, but long-term data are
lacking. We updated the results of our previous phase II
trial with a minimal follow-up exceeding 7 years.
Methods: This is a prospective single-arm phase II trial. The
main inclusion criteria were pathologically provenNSCLC stage
IV with less than five metastases at primary diagnosis, amend-
able for radical local treatment (surgery or radiotherapy). No
previous response to systemic treatment was needed.
Results: Forty patients were enrolled, 39 of whom were
evaluable (18 men, 21 women); mean age was 62.1 ± 9.2
years (range, 44 to 81 years). Twenty-nine (74%) had N2 or
N3 disease; 17 (44%) brain, 7 (18%) bone, and 4 (10%)
adrenal gland metastases. Thirty-five (87%) had a single
metastatic lesion. Thirty-seven (95%) of the patients
received chemotherapy as part of their primary treatment.
Median overall survival (OS) was 13.5 months (95% con-
fidence interval: 7.6–19.4 months); 1-, 2-, 3-, 5-, and 6- year
OS was 56.4%, 23.3%,12.8%, 10.3%, 7.7%, and 5.1%,
respectively. Median PFS was 12.1 months (95% confidence
interval: 9.6–14.3 months); 1-, 2-, 3-, 5-, and 6- year OS was
51.3%, 13.6%, %,12.8%, 7.7%, 7.7%, and 2.5%, respec-
tively. Only three patients (7.7%) had a local recurrence.Journal of Thoracic Oncology Vol. 13 No. 12: 1958-1961Conclusions: In patients whowere not selected according to
response to systemic treatment, the PFS at 5 years was 8%.
Entering patients in trials combining local therapywith novel
systemic agents (e.g., immunotherapy) remains mandatory.
 2018 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: Non-small cell lung cancer; oligometastases;
long-term survival; phase II trial
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Since the seminal paper of Hellman and Weichsel-
baum1 describing an intermediate state between pa-
tients with localized cancer and those with overt distant
metastases, there is increasing interest in the treatment
of synchronous oligometastases, also of patients with
NSCLC. Many retrospective series suggested that a sub-
stantial proportion of highly selected patients are alive
after 5 years, in subgroups nearly exceeding the overall
survival (OS) of unselected patients with localized dis-
ease.2,3 Prospective trials, including ours, also suggested
that long-term progression-free survival (PFS) would be
possible by treating patients with a few metastases with
systemic therapy and radical local treatment with merely
acute, reversible side effects.4-6 In our trial, we reported
after a median follow-up of 27.7 ± 10.5 months (mean,
28.3 months; minimum 16.7 months, maximum 46.1
months), a median OS of 13.5 months (95% confidence
interval [CI]: 7.6–19.4 months), with a 1-year OS of
56.4%, a 2-year OS of 23.3%, and a 3-year OS of 17.5%.
The median PFS was 12.1 months (95% CI: 9.6–14.3
months) with a 1-year PFS of 51.3%, and a 2- and 3-year
PFS of 13.6%.4
Two randomized phase II studies with as primary
endpoint PFS showed an increased PFS by adding a
radical local treatment to systemic therapy in patients
responding to systemic therapy, but long-term PFS and
OS data are lacking.5,6
As we have now reached a minimum follow-up of 7
years of patients included in our previously published
phase II study, we here report the long-term PFS and OS.Patients and Methods
The details have been published previously.4 This
was a prospective single-arm phase II trial (NCT
01282450). The main inclusion criteria were pathologi-
cally proven NSCLC stage IV with less than five metas-
tases at primary diagnosis, eligible for radical local
treatment (surgery or radiotherapy). No previous
response to systemic treatment was required.
Patients were staged with a whole body 18F-
deoxyglucose–positron-emission tomography–computed
tomography (CT) scan and a CT with intravenous
contrast or a contrast-enhanced magnetic resonance
image of the brain. Pathologic confirmation of at least
one distant metastasis was mandatory, unless for brain
metastases only when the multidisciplinary team
considered this diagnosis as “most likely.”
Both surgery and radiotherapy for the primary tumor
and for distant metastases were allowed in the same
patient. The radiotherapy biologic dose was at least 60
Gy (except for brain metastases). Systemic treatment
was not mandatory.The primary endpoint was OS at 2- and 3-years,
the secondary endpoints PFS, dyspnea, dysphagia, and
patterns of recurrence.
Results
Patients
The details of the patients and the primary and sec-
ondary endpoints have been published previously.4
Between July 27, 2006, and July 23, 2010, 40 patients
were enrolled, 39 of whom were evaluable (18 men, 21
women), with a mean age of 62.1 ± 9.2 years (range, 44
to 81 years). Twenty-nine (74%) had N2 or N3 disease.
Seventeen patients (44%) had brain metastases, 7 (18%)
bone, and 4 (10%) adrenal gland metastases. Thirty-five
(87%) had only a single metastatic lesion. Thirty-seven
(95%) of the patients received chemotherapy as part
of their primary treatment. The current analysis was
performed on May 5, 2018.
From the 17 patients with brain metastases, 4
received resection, and the rest received stereotactic
radiosurgery. All patients with bone or solitary pleural
metastases or the patient with a solitary adrenal
metastasis that was irradiated were treated with twice-
daily 1.8 Gy fractions, mostly to a dose of 54 Gy, again
reflecting the era of the trial, when stereotactic radio-
therapy for bone or adrenal metastases had not yet been
implemented. Extrathoracic lymph node metastases and
the patient with a metastasis in the left teres major was
treated for the metastasis with the same fractionation
schedule.
Reflecting the period in which this study was
performed, only three patients were tested for an EGFR
mutation. One of these patients was treated with gefiti-
nib. One patient received erlotinib as second-line
therapy without mutation testing.
Overall and PFS
The median OS was 13.5 months (95% CI: 7.6–19.4
months). The 1-, 2-, 3-, 4-, 5, and 6-year OS rates were
56.4%, 23.3%, 12.8%, 10.3%, 7.7%, and 5.1% (95% CI:
0% – 11.9%; two patients), respectively. The median PFS
was 12.1 months (95% CI: 9.6–14.3 months). The 1-, 2-,
3-, 4-, 5, and 6-year PFS rates were 51.3%, 13.6%,12.8%,
7.7%, 7.7%, and 2.5% (95% CI: 0% – 7.4%; one patient),
respectively (Fig. 1).
Characteristics of Patients With a PFS at 5 Years
From the 3 of 39 patients with a PFS after 5 years,
one had initially a squamous cell cancer cT2N2 with a
single pathologically proven bone metastasis in the
sternum. He developed an adenocarcinoma in the
contralateral lung 71 months after the first diagnosis.
One patient had a NSCLC-NOS cT4N0 with a single
Figure 1. (A) Overall survival. (B) Progression-free survival.
1960 De Ruysscher et al Journal of Thoracic Oncology Vol. 13 No. 12adrenal metastasis that was removed by surgery and
developed a squamous cell cancer of the tongue after
70 months, and one a cT1N2 adenocarcinoma with a
pathologically proven contralateral lung adenocarci-
noma with a similar morphological appearance,
however, without genetic comparison. The latter patient
is still free of disease.
Patterns of Recurrence
Despite the fact that no extracranial metastases
were treated with stereotactic radiotherapy, only
three patients (7.7%) had a local recurrence, all in the
planning target volume (“in field”) of their primary
tumor. One of these patients received gefitinib, one
chemotherapy, and one best supportive care. No local
recurrence occurred in the involved lymph nodes. All
other recurrences appeared at previously identified
distant metastatic sites.
Second Primary Cancers
Two patients developed a second primary cancer:
one patient a tongue carcinoma after 70 months and one
developed an adenocarcinoma in the contralateral lung
71 months after the first diagnosis. Both patients died of
their second cancer.
Treatment at First Relapse
Two patients were treated with an EGFR-tyrosine
kinase inhibitor (TKI) (one gefitinib and one erlotinib)
at first progression. Ten patients received only best
supportive care (including palliative radiotherapy)because of a poor performance status, nine patients
received platinum-based chemotherapy, five stereotactic
radiosurgery for brain relapse (one with chemotherapy)
and seven whole brain radiotherapy (one whole brain
radiotherapy alone and six with chemotherapy). None
received immune therapy.
Conclusions
To the best of our knowledge, this is the first report
of a prospective study on the PFS and OS beyond 5 years
in NSCLC patients with oligometastases. These data are
important because the major aim of adding a radical
local treatment to systemic therapy is to prolong the PFS
and to achieve a long-term OS in some patients. In our
study, approximately 8% of the patients achieved a PFS
after 5 years. We believe that the OS results at 5 years
were not affected by the second-line treatment. Reflect-
ing the period in which the trial was open (2006–2010),
only two patients received a TKI and none immune
therapy. Most patients had treatment failure at distant
sites, indicating the need to optimize the systemic
treatment. Because of the promising results of immune
treatment on long-term OS and the synergy between
chemotherapy and radiotherapy and immune therapy,
trials with combined modality treatment are obvious.7-10
Entering patients in trials designed for oligometastases
is therefore essential.
Offering a radical treatment to patients with syn-
chronous oligometastases outside of a clinical study is
reasonable when there are no trial options, provided that
the patient is in a good general condition and is aware of
the still generally dismal results, although a prolonged
December 2018 PFS and OS Beyond 5 Years of NSCLC 1961PFS may be envisaged.5,6 Although there is no consensus
on the definition of oligometastases, nearly all our pa-
tients had only a single metastasis. Even then, a 5-year
PFS of only 8% could be obtained; this underscores
the need for cautious patient selection. Selection for
radical local therapy could be improved by selecting only
oligometastatic patients responding to induction treat-
ment (chemotherapy or a TKI), as was done in the two
randomized phase II trials.5,6
In conclusion, a radical approach to patients with
oligometastases leads to a definite, but small proportion
of 5-year survivors. Improvements in systemic therapy
to decrease distant failures are needed.Acknowledgments
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